Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
28 pending office actions • 23 art units • 28 examiners • 0 of 28 (0%) have an AI response strategy ready • 33 patents granted in the last 365 days
The Cleveland Clinic Foundation has 29 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 29 distinct examiners and 24 distinct art units, indicating that the current prosecution workload is spread broadly across examiner assignments and technical classifications rather than concentrated in a small examination group.
PERRY, MONICA L is the busiest examiner, with 1 pending matter. Because the busiest examiner has only 1 matter, the available data does not identify a dominant examiner-level concentration. Counsel may therefore need a distributed docketing approach that tracks separate examiner and art-unit practices across the portfolio.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §101 + other | 4 (14%) |
| §103 only | 7 (25%) |
| §112 only | 1 (4%) |
| Double-patenting + other | 4 (14%) |
| Multi-statute (no §101) | 11 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERRY, MONICA L | 1 | 56.1% | +37.3% |
| SINGH, ESVINDER | 1 | 77.4% | +23.2% |
| NEGRELLIRODRIGUEZ, CHRISTINA | 1 | 89.0% | +10.5% |
| SHENG, CHAO | 1 | 65.0% | +26.6% |
| BOOKER, KELVIN | 1 | 79.1% | +6.8% |
| PATEL, OM | 1 | 58.0% | +52.6% |
| OAKES, JUSTIN MONTGOMERY | 1 | 100.0% | +0.0% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| ZHANG, DUAN | 1 | 61.2% | +18.9% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783359 | APPARATUS AND METHOD FOR USE OF FLUID FLOW DEVICE | LE, QUYNH DAO | 31d overdue |
| 18003807 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | LEE, CHIHYI NMN | 6d |
| 18556564 | PROTEASE INHIBITORS AND METHODS OF USE | BARSKY, JARED | 13d |
| 19055951 | SYSTEMS AND METHODS FOR USE WITH MRI-GUIDED FOCUSED ULTRASOUND | SHENG, CHAO | 20d |
| 19262634 | HYBRID CONTROL OF A ROBOTIC SYSTEM | SINGH, ESVINDER | — |
| 19077527 | RETRACTOR SYSTEM FOR ABDOMINAL-WALL REPAIR | NEGRELLIRODRIGUEZ, CHRISTINA | — |
| 18956213 | IDENTIFYING PATIENTS FOR INTENSIVE HYPERGLYCEMIA MANAGEMENT | BOOKER, KELVIN | — |
| 18916290 | METHODS FOR SENSING AND ANALYZING IMPACTS AND PERFORMING AN ASSESSMENT | PATEL, OM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19055951 | SYSTEMS AND METHODS FOR USE WITH MRI-GUIDED FOCUSED ULTRASOUND | SHENG, CHAO | 20d |
| 19157779 | HEAD FIXATION DEVICE | PERRY, MONICA L | — |
| 19262634 | HYBRID CONTROL OF A ROBOTIC SYSTEM | SINGH, ESVINDER | — |
| 19077527 | RETRACTOR SYSTEM FOR ABDOMINAL-WALL REPAIR | NEGRELLIRODRIGUEZ, CHRISTINA | — |
| 18916290 | METHODS FOR SENSING AND ANALYZING IMPACTS AND PERFORMING AN ASSESSMENT | PATEL, OM | — |
| 18675612 | GENERATING HUMAN PODOCYTE CELLS | MONTANARI, DAVID A | — |
| 18640197 | SYNTHETIC TABULAR NEURAL GENERATOR | ZHANG, DUAN | — |
| Art Unit | Apps |
|---|---|
| 3797 | 2 |
| 1672 | 2 |
| 1625 | 2 |
| 1628 | 2 |
| 1643 | 2 |
| 3644 | 1 |
| 3657 | 1 |
| 3773 | 1 |
| 2119 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19157779 | HEAD FIXATION DEVICE | PERRY, MONICA L | 3644 | §112 | Non-Final OA | — | Pending | Aug 19, 2025 |
| 19262634 | HYBRID CONTROL OF A ROBOTIC SYSTEM | SINGH, ESVINDER | 3657 | §103§112Other | Non-Final OA | — | Pending | Jul 08, 2025 |
| 19077527 | RETRACTOR SYSTEM FOR ABDOMINAL-WALL REPAIR | NEGRELLIRODRIGUEZ, CHRISTINA | 3773 | §102§103 | Non-Final OA | — | Pending | Mar 12, 2025 |
| 19055951 | SYSTEMS AND METHODS FOR USE WITH MRI-GUIDED FOCUSED ULTRASOUND | SHENG, CHAO | 3797 | §102§103 | Final Rejection | 20d | Pending | Feb 18, 2025 |
| 18956213 | IDENTIFYING PATIENTS FOR INTENSIVE HYPERGLYCEMIA MANAGEMENT | BOOKER, KELVIN | 2119 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18916290 | METHODS FOR SENSING AND ANALYZING IMPACTS AND PERFORMING AN ASSESSMENT | PATEL, OM | 3791 | §101§103§112 | Non-Final OA | — | Pending | Oct 15, 2024 |
| 18891486 | SYSTEM AND METHOD FOR DIAGNOSING INFLAMMATORY BOWEL DISEASE STATE AND SEVERITY | OAKES, JUSTIN MONTGOMERY | 2662 | §101§103 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18675612 | GENERATING HUMAN PODOCYTE CELLS | MONTANARI, DAVID A | 1632 | §101 | Non-Final OA | — | Pending | May 28, 2024 |
| 18640197 | SYNTHETIC TABULAR NEURAL GENERATOR | ZHANG, DUAN | 3699 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18701156 | MRNA VACCINE DESIGN VIA THE ALTERATION OF CODON USAGE | CHESTNUT, BARRY A | 1672 | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18687993 | TOPICAL DRUG TREATMENT TO PREVENT OR REDUCE CORNEAL SCARRING | OH, TAYLOR V | 1625 | §103 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18392491 | SYSTEMS AND METHODS TO IMPROVE SLEEP DISORDERED BREATHING USING CLOSED-LOOP FEEDBACK | TEJANI, ANKIT D | 3796 | §103Other | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18528348 | GENERATING QUIESCENT HEPATIC STELLATE CELLS AND THEIR USE IN LIVER MODELS | LARA, CAROLINE MONSERRAT | 1633 | §102§103§112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18566802 | NON-CONTACT LITHOTRIPSY USING PHOTONIC NANOPARTICLES | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §102§103§112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18556564 | PROTEASE INHIBITORS AND METHODS OF USE | BARSKY, JARED | 1628 | §102§112 | Final Rejection | 13d | Pending | Oct 20, 2023 |
| 18478684 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | MAHLUM, JONATHAN DAVIS | 1625 | §103§112DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18275797 | MICRO RNA LIVER CANCER MARKERS AND USES THEREOF | YU, TIAN NMN | 1681 | §101§103 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18226698 | SYSTEM AND METHOD FOR EXTRACTION OF JOINT-SPECIFIC MOVEMENT CAPACITY AND MOTION SIGNATURE FROM IMAGING | CELESTINE, NYROBI I | 3798 | §103 | Final Rejection | — | Pending | Jul 26, 2023 |
| 18252928 | ANTI-CD6 ANTIBODY CONJUGATES FOR TREATING T-CELL MEDIATED DISORDERS AND T-CELL LYMPHOMA/LEUKEMIA | CHATTIN, AMY MARIE | 1643 | §103§112 | Final Rejection | — | Pending | May 15, 2023 |
| 18252612 | POLYMORHPISM DETECTION FOR GLIOBLASTOMA DETECTION AND TREATMENT | BUCHANAN, BAILEY CHEYENNE | 1682 | §103 | Final Rejection | — | Pending | May 11, 2023 |
| 18111138 | PROTECTIVE COVER | DANIEL, ANTARIUS S | 3783 | §103§112 | Non-Final OA | — | Pending | Feb 17, 2023 |
| 18169293 | AMHR2-ED CANCER VACCINE FORMULATIONS | DUFFY, BRADLEY | 1643 | §103DP | Final Rejection | 23d overdue | Pending | Feb 15, 2023 |
| 18003807 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | LEE, CHIHYI NMN | 1628 | §102§103§112Other | Non-Final OA | 6d | Pending | Dec 29, 2022 |
| 17854597 | RADIOPAQUE TISSUE MARKER | TALTY, MARIA CHRISTINA | 3797 | §103 | Final Rejection | — | Pending | Jun 30, 2022 |
| 17783359 | APPARATUS AND METHOD FOR USE OF FLUID FLOW DEVICE | LE, QUYNH DAO | 3781 | §103§112 | Final Rejection | 31d overdue | Pending | Jun 08, 2022 |
| 17609957 | INDUCED HUMAN COLITIC ORGANOIDS | ROGERS, ERIC JASON | 1638 | §103§112 | Final Rejection | — | Pending | Nov 09, 2021 |
| 17488384 | RAPID TEST SYSTEM FOR VIRAL AND BACTERIAL INFECTIONS | JADHAO, SAMADHAN JAISING | 1672 | §103 | Final Rejection | 12d | Pending | Sep 29, 2021 |
| 17047497 | METHODS AND COMPOSITIONS FOR TH9 CELL MEDIATED CANCER TREATMENT | ESSEX, LAURA ANN | 1675 | §103 | Non-Final OA | 13d | Pending | Oct 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Cleveland Clinic Foundation has 28 pending office actions as of October 2026, spread across 23 art units and 28 examiners.
Monica L Perry has the most, with 1 of The Cleveland Clinic Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
